Sanofi - American Depositary Shares (SNY)

Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates.

U.S. Health Secretary Robert F. Kennedy Jr. has championed "medical freedom" while simultaneously limiting access to COVID-19 vaccines and restricting food stamp purchases, creating what public health experts call a dichotomy in his approach to healthcare policy.

Kymera's KT-621 achieved rapid, deep STAT6 degradation and showed a strong safety profile in Phase 1, with the next trials planned through early 2026.

Sanofi will pay $129 per share in cash at closing, representing a 27% premium to Blueprint’s closing price on Friday of $101.35.

Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved efficacy and safety profile.

Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.

U.S. stock futures fell on Monday after a mixed close on Friday. Futures of major benchmark indices were trading lower in premarket.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study.

Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not meet its main goal.

RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed.

According to Reuters, operations at the new facility are expected to begin by the end of 2027.

SANOFI-ADR (SNY) offers strong profitability, an attractive dividend, and undervalued metrics, making it a compelling choice for value investors in the pharmaceutical sector.

Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.

The company is working on an Alzheimer's treatment that increases the activity of TREM2, a neuroinflammation target.

Under the terms of the deal, Sanofi will acquire all outstanding common shares of Vigil for $8 per share in cash at closing.

Sanofi (SNY) to acquire Vigil Neuroscience (VIGL) for $470 million in cash, plus potential $2 per share payout. Acquisition excludes monoclonal antibody program and is expected to be finalized in Q3 2025. VG-3927 showed promise in Phase 1 for Alzheimer's treatment.

Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall.

SANOFI-ADR (SNY) offers a strong 4.27% dividend yield with sustainable payouts, solid profitability, and manageable debt, making it a top pick for income investors.

Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.

Bristol-Myers Squibb will pay $350 million to settle Hawaii's lawsuit over Plavix marketing practices, ending claims without admitting wrongdoing and avoiding trial.